Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases
Moonwalk Biosciences, a biotechnology firm at the forefront of epigenetic and RNA interference (RNAi) research, has successfully closed an oversubscribed…
